文献速递免疫规划慢病防控与筛查卫生政策与健康促进

日本60岁及以上成人呼吸道合胞病毒疫苗接种相关因素:基于互联网的横断面研究

Factors associated with respiratory syncytial virus vaccination among Japanese adults aged 60 years and older: an internet-based cross-sectional study.
PubMed 文献 · Vaccine · 2025-12-15

该研究利用日本COVID-19与社会互联网调查2024数据,纳入8300名60岁及以上成人,其中349人(4.2%)接种RSV疫苗。多因素分析显示较高年龄、与两人以上同住、糖尿病、卒中、COPD、COVID-19或流感疫苗接种史及对RSV疾病和疫苗认知较高与接种率升高相关,但总体覆盖率仍低。

要点

  • 60岁及以上日本成人RSV疫苗接种率为4.2%。
  • 高龄、合并糖尿病、卒中、COPD及COVID-19/流感接种史与接种率升高相关。
  • 对RSV临床 picture、疾病严重性和疫苗适用性认知较高者接种率更高。

核心结论

  • RSV疫苗接种在某些高危老年群体中更普遍,但总体覆盖率仍低,需加强教育和意识提升。

研究设计与样本

  • 基于日本COVID-19与社会互联网调查2024的互联网横断面研究,提取60岁及以上参与者数据,最终纳入8300人。

主要发现

  • 8300名参与者中349人(4.2%)接种RSV疫苗。
  • 调整后,80-84岁年龄组aOR为3.79(95%CI:2.43-5.92),与两人以上同住aOR为1.63(95%CI:1.03-2.57)。
  • 糖尿病aOR为1.59(95%CI:1.20-2.11),卒中aOR为2.29(95%CI:1.29-4.06),COPD aOR为3.00(95%CI:1.67-5.38)。
  • COVID-19疫苗接种aOR为2.38(95%CI:1.81-3.12),流感疫苗接种aOR为2.03(95%CI:1.60-2.57)。
  • 对临床 picture 认知较高aOR为2.37(95%CI:1.89-2.97),疾病严重性认知aOR为3.50(95%CI:2.80-4.38),疫苗适用性认知aOR为5.75(95%CI:4.58-7.22)。

临床怎么用

  • 在老年健康管理中,可重点关注高龄、合并糖尿病、卒中、COPD及有COVID-19或流感疫苗接种史者,同时加强RSV疾病和疫苗知识宣教以提高接种意愿。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Respiratory syncytial virus (RSV) is a common pathogen in young children and older adults. Recently, RSV vaccines have been approved in adults aged 60 years and older and have demonstrated substantial efficacy. However, limited data on older adults receiving the RSV vaccination are available. We aimed to identify potential factors associated with RSV vaccination among adults aged 60 years and older. METHODS: Data from 28,000 respondents of the Japan COVID-19 and Society Internet Survey 2024 were used, and data from participants aged 60 years and older were extracted. The association between RSV vaccination status and potential factors (age, sex, marital status, living status, household income, education, working status, comorbidities, COVID-19/influenza vaccination status, and knowledge about RSV and its vaccine) was evaluated using univariate and multivariate analyses. RESULTS: We included 8300 participants, of whom 349 (4.2 %) received the RSV vaccine. After adjustment, older age (age group "80-84" years, adjusted odds ratio [aOR]: 3.79, 95 % confidence interval [CI]: 2.43-5.92), living with two or more people (aOR: 1.63, 95 % CI: 1.03-2.57), diabetes (aOR: 1.59, 95 % CI: 1.20-2.11), stroke (aOR: 2.29, 95 % CI: 1.29-4.06), chronic obstructive pulmonary disease (aOR: 3.00, 95 % CI: 1.67-5.38), and COVID-19 (aOR: 2.38, 95 % CI: 1.81-3.12) and influenza vaccination (aOR: 2.03, 95 % CI: 1.60-2.57) were significantly associated with an increase in RSV vaccination rates. Additionally, higher vaccination rates were associated with higher knowledge of the clinical picture (aOR: 2.37, 95 % CI: 1.89-2.97), disease severity (aOR: 3.50, 95 % CI: 2.80-4.38), and vaccine eligibility (aOR: 5.75, 95 % CI: 4.58-7.22). CONCLUSIONS: RSV vaccination was more prevalent among older adults in certain high-risk groups. However, overall coverage remains low, and further efforts are needed for educational and awareness initiatives.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Noguchi S, Ishimaru T, Yatera K, et al. Factors associated with respiratory syncytial virus vaccination among Japanese adults aged 60 years and older: an internet-based cross-sectional study. Vaccine. 2025. PMID: 41401602. doi:10.1016/j.vaccine.2025.128114

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。